ADCY9: A Potential Drug Target and Biomarker for Parkinson's Disease

Target Name: ADCY9

NCBI ID: G115

ADCY9

ADCY9: A Potential Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder characterized by symptoms such as tremors, rigidity, and difficulty with movement. It is a debilitating condition that affects millions of people worldwide, primarily as the disease progresses. Although there is currently no cure for Parkinson's disease, the development of new treatments is ongoing. One potential drug target and biomarker for Parkinson's disease is ADCY9, a gene that has not yet been fully studied.

The ADCY9 gene is located on chromosome 12q34 and encodes a protein known as adenylyl cyclase (ADCY9). ADCY9 is a key enzyme in the 尾-adrenergic signaling pathway, which is involved in the regulation of many physiological processes in the body, including cardiovascular, metabolic, and inflammatory responses. It is expressed in various tissues and cells, including the brain, where it plays a crucial role in the regulation of movement and motor behavior.

The 尾-adrenergic signaling pathway is known for its role in the development and progression of Parkinson's disease. Studies have shown that individuals with Parkinson's disease have lower levels of 尾-adrenergic neurotransmitters in the brain, such as dopamine and norepinephrine, compared to healthy individuals. This is thought to contribute to the neurodegenerative symptoms of Parkinson's disease.

In addition to its role in the 尾-adrenergic signaling pathway, ADCY9 has also been shown to play a role in the regulation of many other signaling pathways, including the production of reactive oxygen species (ROS) and the regulation of inflammation. ROS are highly reactive molecules that can damage cellular components and contribute to a variety of diseases, including neurodegenerative disorders.

The role of ADCY9 in the regulation of ROS production and inflammation is thought to be relevant to the development of neurodegenerative diseases, including Parkinson's disease. Studies have shown that individuals with Parkinson's disease have increased levels of ROS and increased neurodegeneration in the brain compared to healthy individuals. This may contribute to the progressive symptoms of Parkinson's disease.

In conclusion, ADCY9 is a gene that has not yet been fully studied, but its potential role in the development and progression of Parkinson's disease makes it an attractive target for future research. The development of new treatments for Parkinson's disease is a critical area of research, and the discovery of new biomarkers and drug targets can help to improve our understanding of the underlying mechanisms of the disease and inform the development of new treatments.

Protein Name: Adenylate Cyclase 9

Functions: Adenylyl cyclase that catalyzes the formation of the signaling molecule cAMP in response to activation of G protein-coupled receptors (PubMed:9628827, PubMed:12972952, PubMed:15879435, PubMed:10987815). Contributes to signaling cascades activated by CRH (corticotropin-releasing factor), corticosteroids and beta-adrenergic receptors (PubMed:9628827)

The "ADCY9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADCY9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets